AAN and AHS Release Updated Adult Migraine Prevention Pharmacotherapy Guideline

This joint AAN/AHS guideline reorganizes migraine preventive selection around evidence confidence, tolerability, safety, and cost while integrating CGRP-targeted agents into first-line options for both episodic and chronic migraine.

📅 Journal publication: Aug 31, 2026 · Last updated: Sep 1, 2026

★ Editor's PickAAN/AHS Migraine Prevention GuidelineAmerican Academy of NeurologyAmerican Headache SocietymigraineCGRP monoclonal antibodiesgepantstopiramatebeta blockersonabotulinumtoxinA Neurology / Neuropharmacology

Background Information

New guidelines optimize migraine prevention with personalized strategies.

This guideline provides updated, evidence-based recommendations for pharmacologic migraine prevention in adults, addressing diverse scenarios such as comorbid conditions and special populations. The guidelines recommend when and how to initiate migraine preventive therapy, including choice of medication and considerations for fibromyalgia, obesity, and pregnancy. Pharmacists can enhance patient care by applying these guidelines to optimize migraine prevention, considering individualized patient factors and potential adverse effects. Updated guidelines aid in personalized migraine prevention, considering individual patient needs and comorbidities.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

View on PubMed →

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Founding member rate

$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.